Decoding Heart Failure with Preserved Ejection Fraction: Unmasking the Mystery
"Dive into the complexities of HFpEF, understand its risk factors, and explore the latest research turning myth into reality."
Heart failure (HF) is a syndrome characterized by the heart's inability to pump enough blood to meet the body's needs. While many associate heart failure with a weakened heart muscle, a significant portion of patients experience heart failure even when their heart's pumping function appears normal. This condition is known as heart failure with preserved ejection fraction (HFpEF).
HFpEF presents a unique challenge to healthcare professionals and patients alike. Unlike other forms of heart failure, its underlying mechanisms are not fully understood, making diagnosis and treatment more complex. The prevalence of HFpEF is substantial, accounting for 30% to 50% of all heart failure cases. Given its frequency and the difficulties in managing it, understanding HFpEF is crucial for improving patient outcomes.
This article aims to demystify HFpEF, exploring its potential causes, risk factors, and current treatment strategies. By translating the latest research into accessible information, we hope to empower individuals to better understand this condition and take proactive steps toward managing their heart health.
A Growing Public-Health Burden
The Heart Failure Society of America’s HF Stats reports track heart failure’s incidence, prevalence, lifetime risk, mortality, and hospitalization rates in the United States. The 2024 update described the problem as increasingly severe, particularly among younger populations, racial and ethnic minority groups, and people with multiple health conditions. HF Stats 2025 continues this epidemiologic and outcomes-focused reporting, underscoring heart failure’s broad impact on U.S. health systems.
A Diagnosis That Requires Multiple Clues
HFpEF is generally approached as a clinical diagnosis that brings together symptoms, signs, cardiac function, and evidence of structural or hemodynamic abnormalities. Because preserved ejection fraction does not by itself explain symptoms, clinicians may need to interpret several findings rather than rely on a single measurement. The absence of source material for this subsection means that specific diagnostic tests, thresholds, and limitations should be treated as context-dependent rather than presented as settled here.
From Ejection Fraction to Phenotype
The modern understanding of heart failure has increasingly distinguished syndromes by ejection fraction rather than treating heart failure as one uniform disorder. HFpEF emerged as a recognizable clinical phenotype as clinicians encountered patients with heart-failure symptoms despite preserved pumping performance. Its history is therefore best viewed as an evolving classification and diagnostic framework, with terminology and boundaries continuing to develop.
What Factors Contribute to HFpEF?
HFpEF is a multifactorial condition, meaning that multiple factors can contribute to its development. It's not simply one problem with the heart, but rather a combination of issues that lead to the heart's inability to function properly. These factors can be broadly categorized into:
- Myocardial hypertrophy and ischemia (thickening and reduced blood flow to the heart muscle)
- Fibrosis and apoptosis (scarring and cell death in the heart tissue)
- Endothelial dysfunction (impaired function of the inner lining of blood vessels)
- Reduced VE Compliance (the heart's ability to relax and fill properly)
- Increased Vascular impedance (resistance to blood flow in the vessels)
- Vascular remodeling (changes in the structure of blood vessels)
- Increased Oxidative stress (an imbalance between free radicals and antioxidants)
- Atherogenesis (the formation of plaque in the arteries)
A Complex and Predominant Syndrome
Recent reviews describe HFpEF as the predominant heart-failure phenotype, particularly among aging populations and people with substantial comorbidity burdens. The condition is characterized by heart-failure symptoms, a left-ventricular ejection fraction of at least 50%, and cardiac or structural abnormalities. Current treatment discussions include diuretics and SGLT2 inhibitors, while diagnosis remains challenging because the syndrome has diverse causes and mechanisms.
Heterogeneity Limits a One-Size-Fits-All Model
HFpEF is increasingly recognized as a complex, systemic syndrome with heterogeneous pathophysiology and substantial morbidity. One 2026 review reports that it accounts for approximately half of global heart-failure cases and is associated with marked symptom burden, frequent hospitalization, and limited disease-modifying options. The existence of multiple national and international guidelines also reflects ongoing variation in how HFpEF should be diagnosed and managed.
HFpEF and HFrEF Are Different Phenotypes
Comparative research distinguishes HFpEF from heart failure with reduced ejection fraction, or HFrEF, using ejection-fraction categories and differences in patient characteristics and comorbidities. One study enrolled 1,861 people with heart failure, including 553 with HFpEF and 1,308 with HFrEF, to examine these differences. Other contemporary analyses focus on whether mortality and heart-failure hospitalization outcomes differ between the two phenotypes, while patient-facing explanations commonly use preserved ejection fraction of 50% or higher and reduced ejection fraction of 40% or lower as practical cutoffs.
Empowering Patients with Knowledge
Understanding HFpEF is the first step toward effective management. While the condition presents complexities, ongoing research continues to shed light on potential mechanisms and treatments. By working closely with healthcare providers, adopting a heart-healthy lifestyle, and staying informed about the latest advancements, individuals with HFpEF can take control of their health and improve their quality of life.
A Multisystem Clinical Challenge
The 2026 American College of Cardiology Expert Consensus Decision Pathway describes HFpEF as a heterogeneous, multisystem syndrome frequently encountered by perioperative clinicians. The updated pathway responds to major advances in diagnosis and therapy and follows the 2023 pathway. The Lancet review likewise identifies HFpEF as a complex clinical syndrome whose diagnosis and management are challenging, with increasing recognition linked to population aging and rising obesity and diabetes.
Mechanisms and Management Are Expanding
Emerging research is examining inflammation, immune activation, metabolic dysfunction, mitochondrial biology, and interactions across multiple organ systems in heart-failure progression. The 2026 ACC update places renewed emphasis on key components of HFpEF management, while the 2025 ACC review notes that diagnosis has been refined over time with more sensitive and specific approaches. These developments suggest that future progress will depend on better mechanistic understanding alongside more precise diagnosis and management.
A Condition Shaped by Many Factors
HFpEF is likely influenced by interacting biological, clinical, and social factors rather than a single pathway. Its broader challenge lies in recognizing a heterogeneous syndrome that may present differently across patients and settings. Without subsection-specific sources, these points should remain general and should not be extended to particular disparities, health-system costs, or policy conclusions.
Symptoms and Daily Burden
For patients, HFpEF can be experienced through persistent heart-failure symptoms and the practical consequences of a condition that is difficult to diagnose and manage. The real-world burden may also include repeated clinical encounters and hospitalization, although its extent varies across individuals. Patient experiences should therefore be understood as diverse rather than reduced to ejection fraction alone.